UT health east Texas HOPE Cancer Center

Tyler, Texas 75708

2 studies enrolling now · 8 studies all time

What they study most

Breast Cancer, Breast Neoplasms, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative, Breast Neoplasms, Triple-Negative, Carcinoma, Non-Small Cell Lung, Colorectal Neoplasms, Cutaneous Squamous Cell Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Exocrine Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

Studies at this site

• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy — Recruiting now
• A Study of Sigvotatug Vedotin in Advanced Solid Tumors — Recruiting now
• Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer — Running, not enrolling
• A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer — Running, not enrolling
• A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) — Completed
• A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors — Stopped early
• Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer — Completed
• Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma — Status unconfirmed